Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 in advanced hematological malignancies
NCT02071888Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telaglenastat in Non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) (3 arms), sponsored by Calithera Biosciences. Primary endpoint: Incidence of adverse events. Started Feb 2014; status: completed.
02
Drugs
telaglenastat
03
Conditions
Non-Hodgkin lymphoma (NHL)multiple myeloma (MM)Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02071888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071888.